Balchem Corp. 10-Q Summary: Quarter Ended March 31, 1998
Business Context and Reporting Period
This Form 10-Q covers the three-month period ended March 31, 1998. Balchem Corporation is a specialty chemical company focused on encapsulated ingredients and specialty products. The financial statements are unaudited and include all normal recurring adjustments. A subsequent event noted in the filing is a three-for-two stock split approved on May 2, 1998, with distribution scheduled for June 3, 1998.
Key Financial Metrics
| Metric | Q1 1998 | Q1 1997 |
|---|---|---|
| Net Sales | $7,735 | $6,835 |
| Gross Margin | $3,330 | $3,070 |
| Operating Income | $1,312 | $1,194 |
| Net Earnings | $831 | $717 |
| Diluted EPS | $0.17 | $0.15 |
| Operating Cash Flow | $775 | $664 |
| Cash and Equivalents (End of Period) | $568 | $31 |
| Long-Term Debt | $550 | $800 |
| Total Assets | $18,837 | $17,593 |
Note: All dollar amounts are in thousands, except per share data.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 13% ($900) driven by higher volumes in specialty products and food encapsulation businesses in domestic markets.
- Margin Pressure: Cost of sales increased 2% as a percentage of sales due to higher costs associated with increased product volumes.
- Operating Expenses: Increased to $2,018 from $1,876, primarily due to higher medical plan costs and recruiting/relocation expenses.
- Profitability: Net earnings rose 16% ($114) to $831. Interest expense decreased from $43 to $28 due to debt reduction.
- Balance Sheet: Long-term debt was reduced by approximately $350. Inventory levels increased significantly, with raw materials rising from $836 to $1,360.
Outlook, Risks, and Management Commentary
- Capital Expenditures: The company is expanding capacity for its encapsulated choline chloride product line, expected to be online in Q3 1998. Total capital expenditures for 1998 are projected at approximately $1,300.
- Liquidity: The company maintains $2,000 in committed but unutilized credit facilities. Management states there are no known demands or uncertainties that will materially affect liquidity.
- Contingencies: The company has capitalized costs related to a 1994 customer list purchase. Future payments are contingent on a complex revenue formula and are projected to be of similar magnitude for the remainder of 1998. The agreement terminates in June 2004.
- Accounting Standards: The company adopted SFAS No. 131 and SFAS No. 132 effective January 1, 1998. These are disclosure-only standards and do not impact financial position. New SOPs regarding software costs and start-up activities are not expected to have a material effect.
Investor Verification Checklist
- Verify the impact of the three-for-two stock split on share count and per-share metrics in future filings.
- Monitor the timing and cost of the choline chloride plant expansion to ensure it aligns with the projected Q3 1998 launch.
- Review the formula for contingent payments on the 1994 customer list purchase to assess future cash outflow risks.
- Confirm that the increase in inventory (specifically raw materials) aligns with the reported increase in sales volume.
- Track the utilization of the $2,000 committed credit facility against actual working capital needs.